이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

관상동맥 죽상경화증 성인 환자를 대상으로 한 YN001의 2b상 임상시험 (PURIFY-TIMI 81)

2026년 11월 3일 업데이트: Beijing Inno Medicine Co., Ltd.

관상동맥경화증 성인 환자에서 YN001의 효능 및 안전성을 평가하기 위한 무작위, 다기관, 이중맹검, 평행, 위약대조 2b상 임상시험

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

연구 개요

상세 설명

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

연구 유형

중재적

등록 (추정된)

456

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Alabama
      • Huntsville, Alabama, 미국, 35801-4312
        • 모병
        • Heart Center Research, LLC
        • 연락하다:
    • California
      • Covina, California, 미국, 91740
      • Lincoln, California, 미국, 95648
        • 아직 모집하지 않음
        • Clinical Trials Research
        • 연락하다:
      • Los Alamitos, California, 미국, 90720
        • 아직 모집하지 않음
        • University of California Irvine Medical Center - Cardiovascular Center
        • 연락하다:
      • Stanford, California, 미국, 94305-2200
        • 아직 모집하지 않음
        • Stanford Health Care General Cardiology
        • 연락하다:
      • Torrance, California, 미국, 90502-2006
        • 모병
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • 연락하다:
    • Florida
      • Boca Raton, Florida, 미국, 33434
        • 아직 모집하지 않음
        • Flourish Research - Boca Raton
        • 연락하다:
      • Hialeah, Florida, 미국, 33016-1895
        • 모병
        • New Generation of Medical Research, LLC.
        • 연락하다:
      • St. Petersburg, Florida, 미국, 33709
    • Georgia
      • Atlanta, Georgia, 미국, 30303-3049
        • 아직 모집하지 않음
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • 연락하다:
    • Idaho
      • Meridian, Idaho, 미국, 83642
        • 아직 모집하지 않음
        • St. Luke's Clinic - Idaho Cardiology Associates
        • 연락하다:
    • Illinois
      • Springfield, Illinois, 미국, 62781
        • 아직 모집하지 않음
        • Southern Illinois University School of Medicine
        • 연락하다:
    • Kansas
      • Overland Park, Kansas, 미국, 66211-1215
        • 모병
        • Midwest Heart & Vascular Specialists, LLC
        • 연락하다:
    • Missouri
      • St Louis, Missouri, 미국, 63110-1032
        • 모병
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • 연락하다:
    • North Carolina
      • Raleigh, North Carolina, 미국, 27607
        • 아직 모집하지 않음
        • NC Heart and Vascular Research, LLC
        • 연락하다:
      • Winston-Salem, North Carolina, 미국, 27104-3520
        • 아직 모집하지 않음
        • Javara Inc. - Wake Forest University Health Sciences
        • 연락하다:
    • Ohio
      • Cincinnati, Ohio, 미국, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73135
        • 아직 모집하지 않음
        • South Oklahoma Heart Research, LLC
        • 연락하다:
    • Pennsylvania
      • Camp Hill, Pennsylvania, 미국, 17011
        • 모병
        • Capital Area Research, LLC - Camp Hill
        • 연락하다:
    • Texas
      • Amarillo, Texas, 미국, 79106
        • 모병
        • PharmaTex Research, LLC
        • 연락하다:
      • Carrollton, Texas, 미국, 75010
        • 아직 모집하지 않음
        • Pulse Care Heart and Vascular
        • 연락하다:
      • Tomball, Texas, 미국, 77375
        • 아직 모집하지 않음
        • DM Clinical Research - Dallas
        • 연락하다:
    • An
      • Hefei, An, 중국, 230022
        • 모병
        • The First Affiliated Hospital of Anhui Medical Unversity
        • 연락하다:
          • Jianlong Wang, MD
          • 전화번호: 0086-13681292304
          • 이메일: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, 중국, 230001
        • 모병
        • Anhui Provincial Hospital
        • 연락하다:
          • Kangyu Chen, MD
          • 전화번호: 0086 18056005099
          • 이메일: ustccky@126.com
        • 수석 연구원:
          • Kangyu Chen, MD
        • 부수사관:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100035
        • 모병
        • Beijing Jishuitan Hospital
        • 수석 연구원:
          • Wei Liu, MD
        • 연락하다:
          • Qingwei Ji, MD
          • 전화번호: 0086 18376642655
          • 이메일: jqwl24@163.cou
        • 수석 연구원:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, 중국, 100029
        • 모병
        • Anzhen Hospital
        • 연락하다:
        • 수석 연구원:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, 중국, 101100
        • 아직 모집하지 않음
        • Beijing Luhe Hospital
        • 연락하다:
    • Fujian
      • Fuzhou, Fujian, 중국, 350001
        • 모병
        • Fujian Medical University Union Hospital
        • 연락하다:
        • 수석 연구원:
          • Mingfang Ye, MD
        • 부수사관:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, 중국, 730030
        • 모병
        • The Second Hospital & Clinical Medical School Lanzhou University
        • 연락하다:
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510080
    • Heilongjiang
      • Daqing, Heilongjiang, 중국, 163316
        • 모병
        • Daqing People's Hospital
        • 연락하다:
      • Harbin, Heilongjiang, 중국, 150001
        • 모병
        • The First Affiliated Hospital of Harbin Medical University
        • 연락하다:
        • 수석 연구원:
          • Lu Fu, MD
        • 수석 연구원:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, 중국, 430071
        • 모병
        • Zhongnan Hospital of Wuhan University
        • 연락하다:
        • 수석 연구원:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, 중국, 410008
        • 모병
        • The Second Xiangya Hospital fo Central South University
        • 연락하다:
    • Jilin
      • Changchun, Jilin, 중국, 130033
        • 모병
        • The First Hospital of Jilin University
        • 수석 연구원:
          • Qian Tong, MD
        • 연락하다:
    • Liaoning
      • Shenyang, Liaoning, 중국, 110015
        • 모병
        • The People's Hospital of Liaoning Province
        • 수석 연구원:
          • Ying Liu, MD
        • 연락하다:
    • Shaanxi
      • Xi'an, Shaanxi, 중국, 710068
        • 모병
        • Shaanxi Provincial People's Hospital
        • 연락하다:
    • Shandong
      • Jinan, Shandong, 중국
        • 모병
        • Central Hospital Affiliated to Shandong First Medicial University
        • 연락하다:
          • Guohai Su, MD
          • 전화번호: 0086 19953193319
          • 이메일: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200032
        • 모병
        • Fudan University-Zhongshan Hospital
        • 수석 연구원:
          • Junbo Ge, MD
        • 연락하다:
        • 부수사관:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, 중국, 200001
        • 모병
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • 연락하다:
        • 수석 연구원:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • 모병
        • West China Hospital of Sichuan University
        • 연락하다:
        • 수석 연구원:
          • Yong He, MD
      • Chengdu, Sichuan, 중국, 610072
        • 모병
        • Sichuan Provincial People's Hospital
        • 연락하다:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 300211
        • 모병
        • The Second Hospital of Tianjin Medical University
        • 연락하다:
        • 수석 연구원:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, 중국, 300121
        • 모병
        • Tianjin People's Hospital
        • 수석 연구원:
          • Zhuhua Yao, MD
        • 연락하다:
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310006
        • 모병
        • Zhejiang Provincial People's Hospital
        • 연락하다:
      • Suzhou, Zhejiang, 중국, 215006
        • 모병
        • The First Affiliated Hospital of Soochow University
        • 연락하다:
      • Wenzhou, Zhejiang, 중국, 325000
        • 모병
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • 연락하다:
    • Manitoba
      • Winnipeg, Manitoba, 캐나다, R2H 2A6
        • 아직 모집하지 않음
        • St. Boniface Hospital
        • 연락하다:
    • Ontario
      • London, Ontario, 캐나다, N5A 5A5
        • 아직 모집하지 않음
        • London Health Sciences Centre
        • 연락하다:
      • North York, Ontario, 캐나다, M6B 3H7
        • 아직 모집하지 않음
        • North York Diagnostic and Cardiac Centre
        • 연락하다:
      • Toronto, Ontario, 캐나다, M5B 1W8
        • 아직 모집하지 않음
        • St. Michael's Hospital
        • 연락하다:
      • Vaughan, Ontario, 캐나다, L6A 4N9
        • 아직 모집하지 않음
        • Cardiac Clinic
        • 연락하다:
    • Toronto
      • Toronto, Toronto, 캐나다, M5G 2N2
        • 아직 모집하지 않음
        • Toronto General Hospital - University Health Network
        • 연락하다:
    • New South Wales
      • Penrith, New South Wales, 호주, 2750
        • 모병
        • Cannopy Clinical Research
        • 연락하다:
    • Queensland
      • Brisbane, Queensland, 호주, 4064
        • 모병
        • Core Research Group Pty Ltd.
        • 연락하다:
    • Victoria
      • Altona N., Victoria, 호주, 3025
        • 모병
        • Canopy Clinical Research
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

실험적: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

위약 비교기: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Relative change from baseline in coronary NCPV at Week 13
기간: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

2차 결과 측정

결과 측정
측정값 설명
기간
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
기간: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
기간: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
기간: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
기간: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
기간: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
기간: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
기간: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
기간: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
기간: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
기간: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
기간: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
기간: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
기간: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 7월 31일

기본 완료 (추정된)

2027년 7월 31일

연구 완료 (추정된)

2029년 3월 31일

연구 등록 날짜

최초 제출

2026년 4월 2일

QC 기준을 충족하는 최초 제출

2026년 4월 2일

처음 게시됨 (실제)

2026년 4월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • YN001-203
  • IND 157167 (레지스트리 식별자: Beijing Inno Medicine Co., Ltd.)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다